Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Iodine i 131 + F16SIP** is a combination therapy under investigation for cancer treatment, especially targeting tumors that express fibronectin, including certain thyroid, lung, and other solid tumors. Iodine i 131 is a radioactive isotope commonly used as a radiopharmaceutical for therapy and imaging, particularly in thyroid conditions, where it is selectively taken up by thyroid tissue and emits beta and gamma radiation to destroy targeted cells. F16SIP is an antibody fragment (small immunoprotein, SIP) targeting the extra-domain A of fibronectin, a marker highly expressed in the extracellular matrix of tumor vasculature. When radiolabeled with iodine-131, F16SIP serves as a tumor-targeted radiotherapeutic, delivering cytotoxic radiation directly to tumor tissue and minimizing off-target adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iodine i 131 + F16SIP.